249420 — Il Dong Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual cashflow statement for Il Dong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-13,019	-100,968	-142,170	-80,961	-12,402
Depreciation
Amortisation
Non-Cash Items	32,629	64,410	80,230	37,128	35,983
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-27,907	-4,118	-21,146	-21,101	-21,224
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	19,366	-11,366	-53,541	-36,615	28,293
Capital Expenditures	-19,205	-19,790	-19,605	-18,188	-14,052
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	802	-23,578	-6,830	-2,172	32,510
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-18,403	-43,368	-26,435	-20,360	18,458
Financing Cash Flow Items	—	7,639	-49.3	-70.4	-366
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-4,576	104,316	-3,287	58,152	-27,854
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-4,395	50,022	-83,440	1,112	19,009